Werewolf Therapeutics, Inc.
NASDAQ: HOWL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel J. Hicklin
- Employees
- 46
- Headquarters
- Watertown, United States
- IPO year
- 2021
- Market cap
- $18.2M
- Website
- https://werewolftx.com
Loading HOWL…
Loading profile data…Frequently asked questions about HOWL
What does Werewolf Therapeutics, Inc. (HOWL) do?
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumve...
Where does HOWL trade?
Werewolf Therapeutics, Inc. (HOWL) trades on the NASDAQ Global Select.
What sector is HOWL in?
Werewolf Therapeutics, Inc. (HOWL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Werewolf Therapeutics, Inc.?
Daniel J. Hicklin is the chief executive officer of Werewolf Therapeutics, Inc. (HOWL).
Where is Werewolf Therapeutics, Inc. headquartered?
Werewolf Therapeutics, Inc. is headquartered in United States.
Does HOWL pay a dividend?
Werewolf Therapeutics, Inc. (HOWL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HOWL go public?
Werewolf Therapeutics, Inc. (HOWL) completed its initial public offering in 2021.